View
1.957
Download
6
Tags:
Embed Size (px)
DESCRIPTION
Presented by Dr. A B M Kamrul Hasan in CME of Endocrinology Department, BSMMU on 30th October, 2013
Citation preview
WELCOME to
CME PROGRAM
VILDAGLIPTIN IN THE MANAGEMENT OF TYPE 2 DM
Presenter:DR. A.B.M. KAMRUL HASANMD Final Part (E&M)Department of EndocrinologyBSMMU
DM: GLOBAL BURDEN
• One of the greatest challenges faced by the modern world is diabetes mellitus and its consequences
• Once considered a disease of the West, diabetes is now a global health problem
• The prevalence of diabetes is rapidly rising all over the globe at an alarming rate
6.6
7.97.88.4
0123456789
DM IGT
Pre
vale
nce
(%)
DM and IGT
DM and IGT: World Prevalence and projection 2010 and 2030
2010
2030
International Diabetes Federation. The Diabetes Atlas. 4th ed. Brussels: 2009. Shaw JE et al. Diabetes Res Clin Pract. 2010;87:4-14.
DM: GLOBAL BURDEN
DM and IGT: World prevalence and projection- 2010 and 2030
285344
439472
0
100
200
300
400
500
DM IGT
DM and IGT
Num
ber o
f peo
ple
(milli
ons) 2010
2030
International Diabetes Federation. The Diabetes Atlas. 4th ed. Brussels: 2009. Shaw JE et al. Diabetes Res Clin Pract. 2010;87:4-14.
DM: GLOBAL BURDEN
Top 10 countries for numbers of diabetes in 2010 and 2030 (population aged 20-79 years)
2010 2030
Country No. of DM (millions)
No. of DM (millions)
Country
1 India 50.8 87.0 India 1
2 China 43.2 62.6 China 2
3 USA 26.8 36.0 USA 3
4 Russian Federation
9.6 13.8 Pakistan 4
5 Brazil 7.6 12.7 Brazil 5
6 Germany 7.5 12.0 Indonesia 6
7 Pakistan 7.1 11.9 Mexico 7
8 Japan 7.1 10.4 Bangladesh 8
9 Indonesia 7.0 10.3 Russian Federation
9
10 Mexico 6.8 8.6 Egypt 10
International Diabetes Federation. The Diabetes Atlas. 4th ed. Brussels: 2009.
Shaw JE et al. Diabetes Res Clin Pract. 2010;87:4-14.
Major Metabolic Defects in Type 2 Diabetes
Decreased pancreatic insulin secretion
Peripheral insulin resistance in muscle and fat tissue
Increased hepatic glucose output
Deficient incretin hormonesresponse
Recent research has implicated at least 5 other pathophysiological defects intimately involved in the development of T2DM
• Decreased incretin effects from GIT
• Dysregulated pancreatic α-cell activity
• Lipotoxicity
• Maldaptive kidney responses
• Central neurotransmitter dysfunction
Pathophysiology of T2DM
Hyperglycemia
DeFronzo R. Diabetes 2009;58:773-95.
Hepatic glucose production
glucagon secretion
Neurotransmitter dusfunction
Incretin effect
Glucose uptake
Insulin secretion
Lipolysis
glucose reabsorption
Traditional current oral therapies do not address all islet cell dysfunction
TZD=thiazolidinedione; T2DM=type 2 diabetes mellitusAdapted from DeFronzo RA. Br J Diabetes Vasc Dis. 2003; 3 (Suppl 1): S24–S40.
Pancreatic Islet Dysfunction
Inadequate glucagon
suppression(-cell
dysfunction)
Progressivedecline of β-cell
function
Insufficient Insulin secretion
(β-celldysfunction)
Sulfonylureas
Glinides
TZDsMetformin
Insulin Resistance (Impaired insulin action)
Traditional current oral therapies do not address all islet cell dysfunction
TZD=thiazolidinedione; T2DM=type 2 diabetes mellitusAdapted from DeFronzo RA. Br J Diabetes Vasc Dis. 2003; 3 (Suppl 1): S24–S40.
Pancreatic Islet Dysfunction
Inadequate glucagon
suppression(-cell
dysfunction)
Progressivedecline of β-cell
function
Insufficient Insulin secretion
(β-celldysfunction)
Sulfonylureas
Glinides
TZDsMetformin
Insulin Resistance (Impaired insulin action)
GLP-1DPP-4 inhibitors
GLP-1DPP-4 inhibitors
GLP-1DPP-4 inhibitors
Pharmacologic Targets of Current Drugs Used inthe Treatment of T2DM
-glucosidase inhibitorsDelay intestinal carbohydrate absorption
ThiazolidinedionesDecrease lipolysis in adipose tissue, increase glucose uptake in skeletal muscle and decrease glucose production in liver
SulfonylureasIncrease insulin secretion from pancreatic -cells
BiguanidesIncrease glucose uptakeand decreases hepatic glucose production
Adapted from Cheng AY, Fantus IG. CMAJ. 2005; 172: 213–226.Ahrén B, Foley JE. Int J Clin Pract 2008; 62: 8-14.
GlinidesIncrease insulin secretion from pancreatic -cells
Pharmacologic Targets of Current Drugs Used inthe Treatment of T2DM
-glucosidase inhibitorsDelay intestinal carbohydrate absorption
ThiazolidinedionesDecrease lipolysis in adipose tissue, increase glucose uptake in skeletal muscle and decrease glucose production in liver
SulfonylureasIncrease insulin secretion from pancreatic -cells
GLP-1 analoguesImprove pancreatic islet glucose sensing, slow gastric emptying, improve satiety
BiguanidesIncrease glucose uptakeand decreases hepatic glucose production
DDP-4=dipeptidyl peptidase-4; GLP-1=glucagon-like peptide-1; T2DM=type 2 diabetes mellitusAdapted from Cheng AY, Fantus IG. CMAJ. 2005; 172: 213–226.Ahrén B, Foley JE. Int J Clin Pract 2008; 62: 8-14.
GlinidesIncrease insulin secretion from pancreatic -cells
DPP-4 inhibitorsProlong GLP-1 action leading to improved pancreatic islet glucose sensing, increase glucose uptake
What is Incretin?
• Incretins are gut hormones that enhance glucose stimulated insulin secretion
• Incretin effect designates amplification of insulin secretion following oral glucose load
NATURAL INCRETINS
Two types:
1. Glucose dependent insulinotropic polypeptide (GIP)
2. Glucagon like peptides (GLPs) -GLP-1
These two hormones are rapidly degraded by an enzyme DPP-4
GLP-1 and GIP are the 2 major incretins in human
• Both are peptide hormones (30 and 42 amino acids)
• Secreted from endocrine cells in the small intestinal mucosa
• GLP-1: distal, L-cells (mainly ileum, colon)
• GIP: proximal, K-cells (mainly duodenum)
• Released in response to meal ingestion
GLP-1 positive endocrine L-cells in human small intestine
WHAT IS DPP-4?
• Dipeptidyl Peptidase-4 (DPP-4) is an enzyme found free in the circulation and tethered to endothelium and epithelial cells in most tissues, especially in the intestinal mucosa
• It clears and inactivates GLP-1 and GIP with in few minutes
• It cleaves the N-terminal dipeptide from peptides.
Pancreas
Stomach
Heart
Brain
Liver
Adapted from Baggio & Drucker. Gastroenterol 2007;132;2131–57
Intestine
CardioprotectionCardiac function
Satiety
Gastricemptying
Glucose production
Glucose-dependentinsulin secretion
Insulin synthesis
Glucose-dependent glucagon secretion
β
GLP-1: an incretin hormone with multiple direct effects on human physiology
β
β
α
α
GLP-1
L-cells secrete GLP-1 degraded by DPP-4
EFFECTS OF GLP-1 & GIP
THE PROBLEM
Because of very short half life (1-2 min) therapeutic efficacy is challenged
This led to idea of producing drugs that act as analogue or receptor agonist but longer half life
Another idea was to develops drugs that inhibit DPP-4 enzyme responsible for breakdown of GLP-1 or GIP
Thus one group of drugs is called incretin mimetics and the other group is known as incretin enhancers
GLP-1=glucagon-like peptide-1; GIP=glucose-dependent insulinotropic polypeptide.
Release ofactive incretinsGLP-1 and GIP
Blood glucose in fasting and
postprandial states
Ingestion of food
Glucagon(GLP-1)
Hepatic glucose
production
GI tract
DPP-4 enzyme
InactiveGLP-1
X
Insulin(GLP-1and
GIP)
Glucose-dependent
Glucose depende
ntPancreas
InactiveGIP
Beta cells
Alpha cells
Glucose uptake by peripheral
tissue
Exenatide
Gliptin
NEW THERAPIES: INCRETIN SYSTEM
SITES OF ACTION OF GLIPTINS
INCRETIN MIMETICS AND DPP-4 INHIBITORS:MAJOR DIFFERENCESProperties/effect Incretin mimetics DPP-4 inhibitors
Mechanism of stimulation of insulin secretion exclusively through GLP-1 effect
Yes Unknown
Restitution of insulin secretion (2 phases)
Yes (exenatide) Yes
Hypoglycaemia No No
Inhibition of gastric emptying Yes Marginal
Effect on body weight Weight loss Weight neutral
Side effects Nausea None observed
Administration Subcutaneous Oral
Gallwitz. Eur Endocr Dis. 2006
DIPEPTIDYL PEPTIDASE - 4 INHIBITORS
Drugs belonging to this class:
• Sitagliptin (FDA approved 2006)• Vildagliptin (EU approved 2008)• Saxagliptin (FDA approved 2009)• Linagliptin (FDA approved 2011)
25
VILDAGLIPTIN: PHARMACOKINETICS
• Rapidly absorbed (tmax <2 hours) & highly bioavailable (85%) after oral administration
• Low plasma protein binding (9%)
• Plasma half life 1.5 - 4.5 hours
• Majority (approx. 69%) undergo renal metabolism to inactive metabolites
VILDAGLIPTIN: PHARMACOKINETICS
• Negligible involvement of CYP450 isoforms in metabolism
• Most (85%) is eliminated via urine
• A dose of 50-100mg of vildagliptin provides:o Almost complete inhibition of DDP-4 for
approximately 12 hourso About 40% inhibition by 24 hours
| Presentation Title | Presenter Name | Date | Subject | Business Use Only
28
Series10
5
10
15
20
GIP
AU
C (
nm
ol/
L*2
40
min
)
Series10.0
0.5
1.0
1.5
2.0
2.5
3.0
GL
P-1
AU
C (
nm
ol/L
*24
0 m
in)
Secretion of incretins decreased in IGT and T2DM
T2DM patients vs healthy individuals – following meal
GIP=glucose-dependent insulinotropic polypeptide; GLP-1=glucagon-like peptide-1; GT=glucose tolerance; T2DM=type 2 diabetes mellitusToft-Nielsen, et al. J Clin Endocrinol Metab 2001: 3717-3723.
P <0.001
P=0.095
NormalGT
ImpairedGT
T2DM
GLP-1 GIP
NormalGT
ImpairedGT
T2DM
| Presentation Title | Presenter Name | Date | Subject | Business Use Only
30
| Presentation Title | Presenter Name | Date | Subject | Business Use Only
31
Β-CELL FUNCTION CONTINUES TO DECLINE REGARDLESS OF INTERVENTION IN T2DM
T2DM=type 2 diabetes mellitus*β-cell function measured by homeostasis model assessment (HOMA)Adapted from UKPDS Group. Diabetes. 1995; 44: 1249–1258.
0
20
40
60
80
100
–5 –4 –3 –2 –1 0 1 2 3 4 5 6
Years since Diagnosis
β-ce
ll Fu
nctio
n (%
)*
Progressive Loss of β-cell Function Occurs prior to Diagnosis
Metformin (n=159)
Diet (n=110)
Sulfonylurea (n=511)
Neonatal rat model of pancreatic islet growth
Adapted from Duttaroy A, et al. Diabetes. 54 (suppl 1): A141.Abstract 572-P.
EFFECT OF VILDAGLIPTIN ON -CELL PRESERVATION AND -CELL REGENERATION
BrdU
-pos
itive
cel
ls /
isle
t are
a (
105 )
Week 1 Vildagliptin decreased islet apoptosis
and increased -cell replication
Week 3Resulted in increased
insulin-positive islet mass
Vehicle
P <0.05
0.04
0.06
0.08
0.10
0.12
0.14
Total islet mass
% is
let a
rea
x pa
ncre
atic
wei
ght (
mg)
Vildagliptin60 mg/kg/d
ApoptosisReplication
0
25
50
75
100
Vehicle Vildagliptin60 mg/kg/d
Vehicle
P <0.05
P <0.001
Vildagliptin60 mg/kg/d
Apop
totic
cel
ls /
isle
t are
a (
105 )
0.0
0.5
1.0
1.5
2.0
2.5
Vehicle Vildagliptin
Insulin
VILDAGLIPTIN ENHANCES ISLET CELL FUNCTION BY INCREASING INSULIN AND DECREASING GLUCAGON SECRETION
OGTT 30 min after single oral dose of vildagliptin (100 mg)
OGTT=oral glucose tolerance test *P <0.01.He YL, et al. J Clin Pharmacol 2007; 47: 633-641.
7.5
12.5
17.5
22.5Glucose (mmol/L)
0
60
80
100
120
40
20
Insulin (pmol/L)
60
80
100
120
140Glucagon(ng/L)
−90 −60 −30 0 30 60 90 120 150 180 210 240 270 300
−90 −60 −30 0 30 60 90 120 150 180 210 240 270 300
−90 −60 −30 0 30 60 90 120 150 180 210 240 270 300
Time
Placebo (n=16)Vildagliptin 100 mg (n=15)
75 g glucose
Dose
VILDAGLIPTIN ENHANCES Β-CELL SENSITIVITY TO GLUCOSE
Vildagliptin 50 mg once dailyPlacebo
Mari A, et al. J Clin Endocrinol Metab 2008; 93: 103-109.
Secr
etion
at 7
mM
glu
cose
(pm
ol/m
in/m
2 )
180
200
220
240
260
-4 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Time (weeks)
Basal secretory tone
45
50
55
60
65
70
75
-4 0 4 8 12 16 20 24 28 32 36 40 44 48 52
Time (weeks)
Glu
cose
sen
sitiv
ity(p
mol
/min
/m2 /
mM
)
Glucose sensitivity
12
14
16
18
20
22
24
4.0 8.0 12.0 16.0 20.0 24.0 28.0
Glucose (mmol/L)
Glu
cago
n (p
mol
/L)
Placebo wk 0 (n=14)Placebo wk 12 (n=14)
Vilda wk 0 (50 mg twice daily, n=14)Vilda wk 12 (50 mg twice daily, n=14)
12
14
16
18
20
22
24
4.0 8.0 12.0 16.0 20.0 24.0 28.0
Glucose (mmol/L)
Glu
cago
n (p
mol
/L)
* * **
Vildagliptin Placebo
wk=week; vilda=vildagliptin*P <0.05 vs wk 0.Data on file, Novartis Pharmaceuticals, LAF237A2344.
VILDAGLIPTIN ENHANCES Α-CELL SENSITIVITY TO GLUCOSE
VILDAGLIPTIN ENHANCES INSULIN SENSITIVITY
Series14.0
4.5
5.0
5.5
6.0
6.5
7.0
Duration: 6 weeksVildagliptin vs placebo
Glu
cose
Rd
(mg/
kg•m
in)
Placebo (n=16)
Vildagliptin 50 mg twice daily (n=16)
Insulin infusion 80 mU/m2•min
Mean Rd difference=0.7 mg/kg•min
Rd=rate of disappearance*P <0.05.Azuma K, et al. J Clin Endocrinol Metab 2007; [Epub].
*6.1
5.4
Hyperinsulinemic euglycaemic clamp
Vildagliptin improves postprandial lipid and lipoprotein metabolism
TG=triglycerides; vilda=vildagliptinMatikainen N, et al. Diabetologia 2006; 49: 2049-2057.
Before vilda, week 0 (n=13)
Vilda 50 mg twice daily,week 4 (n=15)
0.8
0.6
0.4
0.2
0.0−1 0 1 2 3 4 5 6 7 8
0.08
0.06
0.04
0.02
0.00−1 0 1 2 3 4 5 6 7 8
Time (h)
0.50
0.40
0.30
0.20
0.10
0.00−1 0 1 2 3 4 5 6 7 8
Time (h)
4.0
3.5
3.0
2.52.0
1.51.0
−1 0 1 2 3 4 5 6 7 8
Plasma TG Chylomicron TG
Chylomicron apo B-48 Chylomicron cholesterol
mm
ol/L
mm
ol/L
mm
ol/L
mg/
L
0 12 24 52
Time (week)
* * †
0 12 24 52
Time (week)
* * *
pmol
/L 3
0 m
in/(
mm
ol/L
)
0 12 24 52
Time (week)
* *m
L · m
in-1
· m
-2
Insulinsecretio
n
Insulin sensitivit
y
Adaptation
index
VILDAGLIPTIN ENHANCES Β-CELL FUNCTION AND INSULIN SENSITIVITY OVER 52 WEEKS
Patients on stable metformin therapy
*P <0.05 vs placebo; †P <0.01 vs placebo.Adapted from Ahrén B, et al. Diabetes Care 2005; 28: 1936–1940.
Vildagliptin 50 mg daily / metforminPlacebo / metformin
nmol
C-pe
ptide
· m
mol
gluc
ose-1
· m
L-1 ·
m-2
300
250
275
200
225
0.050
0.040
0.045
0.025
0.030
0.035
14
10
12
6
8
| Presentation Title | Presenter Name | Date | Subject | Business Use Only
40
| Presentation Title | Presenter Name | Date | Subject | Business Use Only
41
| Presentation Title | Presenter Name | Date | Subject | Business Use Only
42
| Presentation Title | Presenter Name | Date | Subject | Business Use Only
43
| Presentation Title | Presenter Name | Date | Subject | Business Use Only
44
| Presentation Title | Presenter Name | Date | Subject | Business Use Only
45
| Presentation Title | Presenter Name | Date | Subject | Business Use Only
46
| Presentation Title | Presenter Name | Date | Subject | Business Use Only
47
| Presentation Title | Presenter Name | Date | Subject | Business Use Only
48
| Presentation Title | Presenter Name | Date | Subject | Business Use Only
49
| Presentation Title | Presenter Name | Date | Subject | Business Use Only
50
| Presentation Title | Presenter Name | Date | Subject | Business Use Only
51
COMPARISON OF OADs
VECTOR: Results 1
• Hypoglycaemic events (HE)• No patients treated with Vildagliptin experienced hypos including no severe events,
compared with 34 hypos in 15 patients, including one severe event with SU– Mean between-group difference in patients who experienced at least one HE was –41·7% (p = 0·0002)
53 1. VECTOR. doi:10.1185/03007995.2011.579951
VECTOR: Results1
• HbA1c• Vildagliptin significantly lowered HbA1c (7·7% to 7·2%) versus SU (7·2% to 7·3%) post-
Ramadan. The between group difference being −0·5% (p = 0·0262)
1. VECTOR. doi:10.1185/03007995.2011.579951
VECTOR: Results1
• Adherence• The mean number of missed doses was markedly lower with Vildagliptin than with
SU (0·2 vs 7·6; between-group difference −7·4 doses; p = 0·0204). That is, on average, patients had 7 fold more missed doses with SUs than Vildagliptin
1. VECTOR. doi:10.1185/03007995.2011.579951
Only 1 patient in the Vildagliptin group missed at least one dose, compared with 10 patients in the SU group
Vildagliptin Vs Other DPP-4i
Vildagliptine Vs. Sitagliptine & Sexagliptine: Powerful 1.1% reduction in HbA1c
Superior HbA1c reduction data from 2 separate studies with different baseline HbA1c values2
Vildagliptine Vs. Sitagliptine:Longer duration of DPP-4 binding & increased Active GLP 1 than sitagliptin
Tight substrate-like binding of galvus leads to potent DPP-4 inhibition
Greater increases in active GLP-1 levels with GALVUS compared with sitagliptin is likely due to tighter and longer-lasting binding
Vildagliptine Vs. Sitagliptine:
Vildagliptin•Efficacy in add on to metformin: 1.1% HbA1C reduction vs
•Skin reaction not observed
•Durability over 02 years
Sitagliptin•Efficacy in add on to metformin: 0.7% HbA1C reduction
•Hypersensitivity reaction observed in post marketing
•Durability 01 year
Recent Advancement of Vildagliptin Labeling:•No more Caution in CHF•Recommended in moderate to severe renal impairment also
VILDAGLIPTIN APPROVED IN EU FOR T2DM PATIENTS WITH MODERATE OR SEVERE RENAL
IMPAIRMENT
• Renal impairment affects approximately 25 percent of patients with T2DM
• Majority of currently available medications are not recommended, contraindicated or have to be taken with caution in this population
VILDAGLIPTIN APPROVED IN EU FOR T2DM PATIENTS WITH MODERATE OR SEVERE RENAL
IMPAIRMENT
• 24-week, multi-center, randomized, double-blind, parallel-group, placebo-controlled study (n=515) assessed the safety and tolerability of vildagliptin (50 mg qd) in patients with type 2 diabetes and moderate or severe renal impairment
• The trial showed that vildagliptin had a similar safety profile to placebo in these patients6 and resulted in significant improvements in glycemic control when added to existing anti-diabetic therapy
VILDAGLIPTIN APPROVED IN EU FOR T2DM PATIENTS WITH MODERATE OR SEVERE RENAL
IMPAIRMENT
TIME COURSE OF HBA1C DURING RESCUE-FREE TREATMENT IN PATIENTS WITH MODERATE RI
TIME COURSE OF HBA1C DURING RESCUE-FREE TREATMENT IN PATIENTS WITH MODERATE RI
Overall summery of AEs by Rx & severity of RI
Summery of common AEs by Rx & severity of RI
VILDAGLIPTIN IN HEPATIC IMPAIRMENT
• The effect of impaired hepatic function on the pharmacokinetics of vildagliptin was studied in subjects with mild, moderate, and severe hepatic impairment based on the Child-Pugh scores (ranging from 6 for mild to 12 for severe) in comparison to subjects with normal hepatic function.
• The exposure to vildagliptin (100 mg) after a single dose in subjects with mild and moderate hepatic impairment was decreased (20% and 8%, respectively), while the exposure to vildagliptin for subjects with severe impairment was increased by 22%.
VILDAGLIPTIN IN HEPATIC IMPAIRMENT
• The maximum change (increase or decrease) in the exposure to vildagliptin is ~30%, which is not considered to be clinically relevant
• There was no correlation between the severity of hepatic function impairment and changes in exposure to vildagliptin
VILDAGLIPTIN IN HEPATIC IMPAIRMENT
• The use of vildagliptin is not recommended in patients with hepatic impairment including patients with a pre-treatment ALT or AST > 2.5x the upper limit of normal
VILDAGLIPTIN IN HEPATIC IMPAIRMENT
• Liver function should be monitored quarterly in the first year and periodically thereafter
• Vildagliptin should be stopped if ALT rises 3 times upper normal limit
TAKE HOME MESSAGE
• Incretins are gut hormones that enhance glucose
stimulated insulin secretion
• Amplification of insulin secretion following oral
glucose load- “incretin effect”
• This effect is severely reduced or lost in type 2 DM
TAKE HOME MESSAGE
• Biologic incretins are ineffective in clinical use
because of short half-life
• Therapeutic benefit is obtained by DPP-4 resistant
GLP-1 analogue and DPP-4 enzyme inhibitors
• Incretin based therapy has shown a new pathway
of treatment of T2DM, with a promise for weight
loss and β cell generation
TAKE HOME MESSAGE
• Gliptins are weight neutral and does not cause hypoglycaemia
• Gliptins may increase beta cell mass in human
• Vildagliptin is safe and effective in type 2 diabetic patients with moderate to severe renal impairment
Acknowledgement
• Prof. Md. Fariduddin Chairman & Course Co-ordinator, Department of Endocrinology, BSMMU
• Dr. M.A. Hasanat Associate Prof, Department of Endocrinology, BSMMU
• Novartis Pharma, Bangladesh
Thank You All
76